A recent report argued that a combination therapy of everolimus and pasireotide (SSTRs agonist) could produce some clinical benefit in progressive MTC (181), according to the expression of SSTRs in MTC cells (SSTR1, SSTR2, and SSTR5) (182). This evidence concerns the gene SSTR1 and medullary thyroid gland carcinoma.